Beurs gesloten -
Nasdaq Stockholm
12:59:33 30-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
1.672
SEK
|
+0,97%
|
|
+9,82%
|
+23,49%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
132.331
|
131.461
|
181.878
|
210.243
|
209.128
|
234.684
|
-
|
-
|
Bedrijfswaarde
1 |
144.340
|
143.328
|
206.261
|
233.166
|
231.638
|
254.583
|
248.123
|
241.142
|
K/w-verhouding
|
97,9
x
|
41
x
|
1.468
x
|
64,3
x
|
35,4
x
|
27,8
x
|
23,2
x
|
20,6
x
|
Dividendrendement
|
2,78%
|
2,8%
|
2,44%
|
2,14%
|
2,15%
|
2,06%
|
2,15%
|
2,24%
|
Marktkapitalisatie/omzet
|
5,43
x
|
4,94
x
|
4,86
x
|
4,74
x
|
4,57
x
|
4,58
x
|
4,28
x
|
4,06
x
|
Bedrijfswaarde/omzet
|
5,92
x
|
5,38
x
|
5,51
x
|
5,26
x
|
5,06
x
|
4,97
x
|
4,53
x
|
4,17
x
|
Bedrijfswaarde/EBITDA
|
21,6
x
|
17,2
x
|
27,2
x
|
25,2
x
|
17,1
x
|
14,3
x
|
12,4
x
|
11,1
x
|
Bedrijfswaarde/FCF
|
72,5
x
|
37,3
x
|
42,3
x
|
26,7
x
|
25,8
x
|
28,4
x
|
21,1
x
|
17,5
x
|
FCF Yield
|
1,38%
|
2,68%
|
2,36%
|
3,74%
|
3,88%
|
3,52%
|
4,75%
|
5,71%
|
Price to Book
|
10
x
|
8,41
x
|
4,24
x
|
5,67
x
|
5,38
x
|
5,72
x
|
4,89
x
|
4,48
x
|
Aantal aandelen (in duizenden)
|
1.311.913
|
1.312.660
|
1.549.159
|
1.549.528
|
1.549.926
|
1.550.231
|
-
|
-
|
Referentieprijs
2 |
100,9
|
100,1
|
117,4
|
135,7
|
134,9
|
150,9
|
150,9
|
150,9
|
Datum van publicatie
|
14/02/20
|
11/02/21
|
10/02/22
|
9/02/23
|
8/02/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
24.384
|
26.617
|
37.417
|
44.351
|
45.811
|
51.238
|
54.797
|
57.833
|
EBITDA
1 |
6.686
|
8.311
|
7.586
|
9.237
|
13.580
|
17.822
|
20.004
|
21.723
|
Bedrijfsresultaat (EBIT)
1 |
6.436
|
7.340
|
9.928
|
13.350
|
14.534
|
16.762
|
18.975
|
20.572
|
Operationele Marge
|
26,39%
|
27,58%
|
26,53%
|
30,1%
|
31,73%
|
32,71%
|
34,63%
|
35,57%
|
Resultaat voor belastingen (EBT)
1 |
1.548
|
3.916
|
-265
|
2.501
|
6.899
|
10.863
|
13.027
|
14.270
|
Nettowinst (verlies)
1 |
1.335
|
3.196
|
112
|
3.288
|
5.961
|
8.519
|
10.195
|
11.616
|
Nettomarge
|
5,47%
|
12,01%
|
0,3%
|
7,41%
|
13,01%
|
16,63%
|
18,61%
|
20,08%
|
WPA
2 |
1,030
|
2,440
|
0,0800
|
2,110
|
3,810
|
5,426
|
6,493
|
7,337
|
Free Cash Flow
1 |
1.990
|
3.838
|
4.872
|
8.717
|
8.984
|
8.965
|
11.787
|
13.765
|
FCF-marge
|
8,16%
|
14,42%
|
13,02%
|
19,65%
|
19,61%
|
17,5%
|
21,51%
|
23,8%
|
Kasstroomconversie (ebitda)
|
29,76%
|
46,18%
|
64,22%
|
94,37%
|
66,16%
|
50,3%
|
58,92%
|
63,37%
|
Kasstroomconversie (nettowinst)
|
149,06%
|
120,09%
|
4.350%
|
265,12%
|
150,71%
|
105,23%
|
115,62%
|
118,5%
|
Dividend per aandeel
2 |
2,800
|
2,800
|
2,870
|
2,900
|
2,900
|
3,106
|
3,240
|
3,376
|
Datum van publicatie
|
14/02/20
|
11/02/21
|
10/02/22
|
9/02/23
|
8/02/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Omzet
1 |
-
|
-
|
-
|
12.011
|
-
|
11.390
|
10.771
|
-
|
10.982
|
11.207
|
-
|
10.879
|
11.416
|
11.492
|
12.024
|
12.679
|
12.709
|
12.966
|
13.563
|
12.820
|
13.395
|
EBITDA
1 |
-
|
-
|
-
|
1.900
|
-
|
2.187
|
1.896
|
-
|
2.579
|
2.574
|
-
|
-
|
3.732
|
-
|
-
|
-
|
4.602
|
4.711
|
6.276
|
-
|
-
|
Bedrijfsresultaat (EBIT)
1 |
-
|
-
|
-
|
3.318
|
-
|
3.961
|
3.365
|
-
|
3.413
|
2.610
|
-
|
3.946
|
4.291
|
3.545
|
2.752
|
4.310
|
4.216
|
4.342
|
3.967
|
-
|
-
|
Operationele Marge
|
-
|
-
|
-
|
27,62%
|
-
|
34,78%
|
31,24%
|
-
|
31,08%
|
23,29%
|
-
|
36,27%
|
37,59%
|
30,85%
|
22,89%
|
33,99%
|
33,18%
|
33,48%
|
29,25%
|
-
|
-
|
Resultaat voor belastingen (EBT)
1 |
-
|
-
|
-
|
-636
|
-
|
553
|
247
|
-
|
922
|
778
|
-
|
2.262
|
2.088
|
1.652
|
897
|
2.800
|
2.489
|
2.959
|
3.074
|
-
|
-
|
Nettowinst (verlies)
1 |
-
|
-
|
-
|
-347
|
-
|
386
|
360
|
-
|
1.640
|
901
|
-
|
1.803
|
1.818
|
1.378
|
959
|
2.179
|
2.396
|
2.337
|
2.463
|
-
|
-
|
Nettomarge
|
-
|
-
|
-
|
-2,89%
|
-
|
3,39%
|
3,34%
|
-
|
14,93%
|
8,04%
|
-
|
16,57%
|
15,93%
|
11,99%
|
7,98%
|
17,19%
|
18,86%
|
18,02%
|
18,16%
|
-
|
-
|
WPA
2 |
-
|
-
|
-
|
-0,2200
|
-
|
0,2500
|
0,2300
|
-
|
1,050
|
0,5800
|
-
|
1,160
|
1,170
|
0,8900
|
0,6200
|
1,410
|
1,537
|
1,503
|
1,584
|
-
|
-
|
Dividend per aandeel
2 |
0,9000
|
1,900
|
0,9000
|
1,970
|
1,970
|
-
|
0,9300
|
0,9300
|
-
|
1,970
|
1,970
|
-
|
0,9300
|
-
|
1,970
|
-
|
0,8775
|
0,7750
|
1,422
|
0,8750
|
0,8750
|
Datum van publicatie
|
30/07/20
|
11/02/21
|
29/07/21
|
10/02/22
|
10/02/22
|
29/04/22
|
29/07/22
|
29/07/22
|
10/11/22
|
9/02/23
|
9/02/23
|
27/04/23
|
28/07/23
|
9/11/23
|
8/02/24
|
25/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
1 |
12.009
|
11.867
|
24.383
|
22.923
|
22.510
|
19.899
|
13.439
|
6.458
|
Nettokaspositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Hefboom (schuld/ebitda)
|
1,796
x
|
1,428
x
|
3,214
x
|
2,482
x
|
1,658
x
|
1,117
x
|
0,6718
x
|
0,2973
x
|
Free Cash Flow
1 |
1.990
|
3.838
|
4.872
|
8.717
|
8.984
|
8.965
|
11.787
|
13.765
|
ROE (netto-inkomsten/eigen vermogen)
|
35,6%
|
36,7%
|
27,5%
|
27,2%
|
29,8%
|
28,8%
|
30,3%
|
30,6%
|
ROA (netto-inkomsten/totale activa)
|
2,19%
|
4,99%
|
8,77%
|
3,26%
|
11,5%
|
9,36%
|
10,6%
|
11,4%
|
Totale activa
1 |
61.015
|
64.053
|
1.277
|
100.924
|
51.935
|
91.041
|
96.275
|
101.688
|
Nettoactief per aandeel
2 |
10,10
|
11,90
|
27,70
|
23,90
|
25,10
|
26,40
|
30,80
|
33,70
|
Cashflow per aandeel
2 |
2,280
|
3,660
|
4,180
|
6,290
|
6,620
|
8,880
|
10,40
|
12,10
|
Capex
1 |
979
|
961
|
1.091
|
1.091
|
1.361
|
2.311
|
2.065
|
1.981
|
Capex/omzet
|
4,01%
|
3,61%
|
2,92%
|
2,46%
|
2,97%
|
4,51%
|
3,77%
|
3,43%
|
Datum van publicatie
|
14/02/20
|
11/02/21
|
10/02/22
|
9/02/23
|
8/02/24
|
-
|
-
|
-
|
Laatste slotkoers
150,9
USD Gemiddelde koersdoel
164,3
USD Spread / Gemiddelde doel +8,86% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| +34,00% | 664 mld. | | +29,29% | 567 mld. | | -7,75% | 354 mld. | | +18,53% | 330 mld. | | +4,95% | 286 mld. | | +4,93% | 199 mld. | | -9,78% | 196 mld. | | -4,89% | 148 mld. | | -11,01% | 145 mld. |
Farmaceutische producten - Andere
|